Results 41 to 50 of about 700,500 (193)

Safety and Immunogenicity of Adenovirus and Poxvirus Vectored Vaccines against a Mycobacterium Avium Complex Subspecies

Vaccines, 2021
Heterologous prime-boost strategies are known to substantially increase immune responses in viral vectored vaccines. Here we report on safety and immunogenicity of the poxvirus Modified Vaccinia Ankara (MVA) vectored vaccine expressing four Mycobacterium
Pedro M. Folegatti, Amy Flaxman, Daniel Jenkin, Rebecca Makinson, Lucy Kingham-Page, Duncan Bellamy, Fernando Ramos Lopez, Jonathan Sheridan, Ian Poulton, Jeremy Aboagye, Nguyen Tran, Celia Mitton, Rachel Roberts, Alison M. Lawrie, Adrian V. S. Hill, Katie J. Ewer, Sarah Gilbert   +16 more
doaj   +1 more source

Optimizing rabies mRNA vaccine efficacy via RABV-G structural domain screening and heterologous prime-boost immunization. [PDF]

NPJ Vaccines
mRNA vaccine has become a promising technology platform for rabies prevention. This study explores the roles of different structural domains of rabies virus glycoprotein (RABV-G) and heterologous prime-boost strategies for enhanced immune responses and ...
Li D, Wang X, Li G, Zhou J, Bian L, Zhao X, Xing L, Zeng J, Cui J, Cui L, Zhang Y, Chen Y.   +11 more
europepmc   +2 more sources

Alternating 3 different influenza vaccines for swine in Europe for a broader antibody response and protection

Veterinary Research, 2022
Heterologous prime-boost vaccination with experimental or commercial influenza vaccines has been successful in various animal species. In this study, we have examined the efficacy of alternating 3 different European commercial swine influenza A virus ...
Anna Parys, Elien Vandoorn, Koen Chiers, Kristien Van Reeth   +3 more
doaj   +1 more source

Heterologous Prime-Boost Immunization Strategies Using Varicella-Zoster Virus gE mRNA Vaccine and Adjuvanted Protein Subunit Vaccine Triggered Superior Cell Immune Response in Middle-Aged Mice. [PDF]

Int J Nanomedicine
Dongdong Li,1 Lijun Bian,1 Lili Cui,2 Jingying Zhou,1 Gaotian Li,1 Xiaoyan Zhao,1 Liao Xing,1 Jiaxing Cui,1 Bo Sun,1 Chunlai Jiang,1,3,4 Wei Kong,1,3,4 Yong Zhang,1,3,4 Yan Chen1,3,4 1National Engineering Laboratory for AIDS Vaccine, School of Life ...
Li D, Bian L, Cui L, Zhou J, Li G, Zhao X, Xing L, Cui J, Sun B, Jiang C, Kong W, Zhang Y, Chen Y.   +12 more
europepmc   +2 more sources

Assessment of an LSDV-Vectored Vaccine for Heterologous Prime-Boost Immunizations against HIV [PDF]

Vaccines, 2021
The modest protective effects of the RV144 HIV-1 vaccine trial have prompted the further exploration of improved poxvirus vector systems that can yield better immune responses and protection. In this study, a recombinant lumpy skin disease virus (LSDV) expressing HIV-1 CAP256.SU gp150 (Env) and a subtype C mosaic Gag was constructed (LSDVGC5) and ...
Ros Chapman, Michiel van Diepen, Nicola Douglass, Shireen Galant, Mohamed Jaffer, Emmanuel Margolin, Phindile Ximba, Tandile Hermanus, Penny L. Moore, Anna-Lise Williamson   +9 more
openaire   +4 more sources

DataSheet_1_In-depth analysis of T cell immunity and antibody responses in heterologous prime-boost-boost vaccine regimens against SARS-CoV-2 and Omicron variant.pdf

, 2022
With the emergence of novel Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Variants of Concern (VOCs), vaccination studies that elucidate the efficiency and effectiveness of a vaccination campaign are critical to assess the durability and ...
Matthias Tenbusch (85322), Stephanie Pfänder (14287934), Ingo Schmitz (520756), Toralf Roch (4240687), Clara Bessen (9117066), Ulrik Stervbo (2557699), Sandra Busse (10938663), Wolfgang Ekkehard Schmidt (14287928), Doris Urlaub (5611730), Markus Hoffmann (223014), Stefan Pöhlmann (142445), Daniel Robert Quast (14287931), Natalie Heinen (10642370), Eike Steinmann (32663), Daniel Todt (777446), Jil Schrader (3364673), Elena Vidal Blanco (14206799), Carsten Hagenbeck (5143943), Moritz Anft (11995520), Nina Babel (844503), Corinna Sophie Marheinecke (14287922), Gert Zimmer (223023), Mara Klöhn (14287925), Arturo Blazquez-Navarro (5203973), Carsten Watzl (208203), Carlos Plaza-Sirvent (11334660)   +25 more
core   +1 more source

Superior neutralizing antibody response and protection in mice vaccinated with heterologous DNA prime and virus like particle boost against HPAI H5N1 virus. [PDF]

PLoS ONE, 2011
BACKGROUND: Although DNA plasmid and virus-like particle (VLP) vaccines have been individually tested against highly pathogenic avian influenza (HPAI) H5N1 viruses, the combination of both vaccines into a heterologous prime-boost strategy against HPAI ...
Heng Ding, Cheguo Tsai, Ramona Alikiiteaga Gutiérrez, Fan Zhou, Philippe Buchy, Vincent Deubel, Paul Zhou   +6 more
doaj   +1 more source

Heterologous prime-boost-boost immunisation of Chinese cynomolgus macaques using DNA and recombinant poxvirus vectors expressing HIV-1 virus-like particles [PDF]

, 2011
Background: There is renewed interest in the development of poxvirus vector-based HIV vaccines due to the protective effect observed with repeated recombinant canarypox priming with gp120 boosting in the recent Thai placebo-controlled trial.
Bridge, S., Skinner, Michael A., Anson, Donald, Dennis, M., Simon H Bridge, Dowall, S., Blanchard, Tom J., Getty, B., Stewart, James, Dennis, Mike J., Dowall, SD, Donald S Anson, Anson, D., Dennis, MJ, Bridge, Simon H., Dowall, Stuart D., Blanchard, Thomas, Stewart, JP, Blanchard, T., Skinner, M., Stewart, James P., James P Stewart, Mike J Dennis, Getty, B, Michael A Skinner, Bridge, SH, Bridge, Simon, Sharpe, Sally, Sharpe, SA, Skinner, MA, Getty, Brian, Brian Getty, Dennis, Mike, Blanchard, Tom, Sharpe, Sally A., Anson, DS, Sally A Sharpe, Skinner, Michael, Stuart D Dowall, Tom J Blanchard, Blanchard, TJ, Anson, Donald S., Stewart, J., Sharpe, S., Dowall, Stuart, Sharpe Sally A, Skinner Michael A, Dowall Stuart D, Dennis Mike J, Blanchard Tom J, Stewart James P, Anson Donald S, Bridge Simon H, Getty Brian   +53 more
core   +1 more source

Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination

Journal of the Formosan Medical Association, 2022
Background/Purpose: Efficacy and safety data of heterologous prime-boost vaccination against SARS-CoV-2 remains limited. Methods: We recruited adult volunteers for homologous or heterologous prime-boost vaccinations with adenoviral (ChAdOx1, AstraZeneca)
Wang-Huei Sheng, Sui-Yuan Chang, Pin-Hung Lin, Ming-Ju Hsieh, Hao-Hsiang Chang, Chien-Yu Cheng, Hung-Chih Yang, Ching-Fu Pan, Si-Man Ieong, Tai-Ling Chao, Jang-Pin Chen, Shu-Hsing Cheng, Shan-Chwen Chang   +12 more
doaj   +1 more source

Heterologous Prime-Boost Vaccination with Commercial FMD Vaccines Elicits a Broader Immune Response than Homologous Prime-Boost Vaccination in Pigs. [PDF]

Vaccines (Basel), 2023
Three commercial vaccines are administered in domestic livestock farms for routine vaccination to aid for foot-and-mouth disease (FMD) control in Korea. Each vaccine contains distinct combinations of inactivated serotype O and A FMD virus (FMDV) antigens: O/Manisa + O/3039 + A/Iraq formulated in a double oil emulsion (DOE), O/Primorsky + A/Zabaikalsky ...
Kim J, Lee SH, Kim HH, Park JH, Park CK.
europepmc   +4 more sources